We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model.
- Authors
Romeo, Maria Anele; Focaccetti, Chiara; Arena, Andrea; Benedetti, Rossella; Di Crosta, Michele; Palumbo, Camilla; Gilardini Montani, Maria Saveria; Santarelli, Roberta; Gonnella, Roberta; D'Orazi, Gabriella; Bei, Roberto; Cirone, Mara
- Abstract
This article discusses the use of the drug Bortezomib in the treatment of primary effusion lymphoma (PEL), a type of non-Hodgkin B cell lymphoma associated with Kaposi's sarcoma-associated herpesvirus (KSHV). The current standard chemotherapy for PEL only provides partial remission in a small percentage of patients. Bortezomib has shown cytotoxic effects against PEL cells in vitro and in mice, prolonging survival and preventing ascites formation. The study also explores the potential of combining Bortezomib with Chloroquine, but the results show a reduction in the therapeutic effect. The findings provide new insights into the mechanisms of Bortezomib and highlight the importance of understanding these mechanisms to improve treatment outcomes for PEL.
- Subjects
BORTEZOMIB; EXUDATES &; transudates; LABORATORY mice; ANIMAL disease models; KAPOSI'S sarcoma-associated herpesvirus; DNA repair
- Publication
Hematological Oncology, 2024, Vol 42, Issue 2, p1
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3262